Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Family Secret (FS) is a company that specialises in making sauces that are low on fat, sugar, calories and contain no added preservatives. The company's seven cooking sauces are listed with retailers including Ocado, Coop Midcounties, Amazon, as well as, hosted on QVC. The company's pouches are recyclable, and it is the process to make them compostable/biodegradable. It aims to be a disruptor in the $605 billion snacks market. FS won the 'Best Pitch' in the West Midlands 2019 via Pitchfest at Venturefest, were finalists for The Midlands region of the Family Business Entrepreneur 2019 via Great British Entrepreneur Awards, and appeared with celebrity chef Gordon Ramsay in a recipe video. The company will use the investment to expand its range of cooking sauces, produce more recipe videos to attract customers, expand sales by making its website more intuitive, and bring out snack boxes.
days to go:
Expired
investment:
£147,070
Altr is an e-commerce startup that specialises in male grooming and cosmetics. It is a brand that is committed to helping men look and feel more confident. The company adopts a B2C business model with the aim to reconstruct male cosmetics from a niche into a mass-market essential. The company retails through its own website and supplies across the UK, the US, Italy, and Spain through Amazon. In December last year, the company recorded a monthly turnover of £45k, doubling sales month on month (Oct-Dec). The funds raised will be used to increase product range and expand internationally.
days to go:
Expired
investment:
£103,530
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.
days to go:
Expired
investment:
£394,680
Vitae London is a fashion brand producing water-resistant, stainless steel casing, and high-quality watches. For every watch sold, the company supports a South African child by providing all the resources they need for education. Vitae London has sold its products in over 30 countries and has distributed over 2,000 items of school uniform to children in need. It has been featured in CNN and BBC, and has been endorsed by Pharrell Williams, Richard Branson and many more high-profile names. The company is raising funds to make key hiring, launch US fulfilment site, and drive marketing channels.
days to go:
Expired
investment:
£109,536
Occuity seeks to develop revolutionary non-invasive screening and monitoring devices for chronic diseases like diabetes and Alzheimer's. It argues that its device safely shines a low power beam of light into the eye and then collects and analyses the return signal to accurately measure structures within the eye and detect changes associated with the onset of the aforementioned diseases. Occuity is targeting three distinct markets, namely Ophthalmology, Disease Screening and Disease Monitoring, which is worth an estimated $35 billion per year. It claims that its 'Occuity Indigo' product enables earlier detection of diabetes and provides a non-contacting, pain-free glucose monitor. Occuity was awarded over £1.5 million as part of the Innovate UK grant for the development of technology within Occuity Indigo. It has also signed a partnership with one of the UK's leading ophthalmic distributors, Birmingham Optical, to distribute its PM1 pachymeter device. It states it will use 42% of the investment towards Research and Development (R&D), 23% towards sales and marketing, 20% towards management and finance, 9% towards managing CAPEX and NRE, and 6% towards paying fees.
days to go:
Expired
investment:
£2,854,857
